

Date: December 30, 2025

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Scrip Code: 530019

Symbol: JUBLPHARMA

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Madam/Sir,

Pursuant to the provisions of Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that Jubilant Generics Limited, a step down wholly owned subsidiary of the Company has made an investment of CAD 30,000 (approx. INR 0.20 crores) in Jubilant Pharmaceuticals Inc., Canada today, i.e. December 30, 2025.

Consequent to the above initial investment, Jubilant Pharmaceuticals Inc. has become a step-down wholly owned subsidiary of the Company.

The required details as per SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as **Annexure-A**.

Date and time of occurrence of event is December 30, 2025 at 05:14 pm.

The above mentioned document will be simultaneously posted on the Company's website at www.jubilantpharmova.com.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary
Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Annexure-A

S. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.;	Name: Jubilant Pharmaceuticals Inc. Country of Incorporation: Canada Turnover – Nil (Yet to commence business operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Not Applicable: Jubilant Pharmaceuticals Inc., became a step down wholly owned subsidiary on making initial investment. The Promoter and Promoter group have no interest except to the extent of shareholding in the Holding Company i.e. Jubilant Pharmova Limited.
3	Industry to which the entity being acquired belongs;	Pharmaceuticals Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To establish branded Generic business in Canada and strengthening Jubilant presence in the Canadian market and resulting in revenue growth.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	No
6	Indicative time period for completion of the acquisition;	Not Applicable
7	Consideration - whether cash consideration or share swap and details of the same;	Initial investment in Cash
8	Cost of acquisition and/or the price at which the shares are acquired;	Initial investment of CAD 30,000 (`Rs. 0.20 cr) to subscribe 30,000 shares of Common Stock



9	Percentage of shareholding/ control acquired and / or number of shares acquired;	100% (wholly owned subsidiary of Jubilant Generics Limited)
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Date of Incorporation - 17.06.2025 under the Canada Business Corporations Act and is located in Canada</p> <p>Initial Investment made on December 30, 2025</p> <p>Last 3 years turnover - not applicable</p>